Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Go back to Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting| (NASDAQ: XENE) | Delayed: 52.10 -0.09 (0.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $52.19 | 52 Week High | $9.75 | |||
| Open | $52.02 | 52 Week Low | $5.65 | |||
| Day High | $53.07 | P/E | N/A | |||
| Day Low | $52.01 | EPS | $0.00 | |||
| Volume | 704,212 | |||||
